DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+16.43%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$4.68B
AUM Growth
+$4.68B
(+4.4%)
Cap. Flow
-$330M
Cap. Flow
% of AUM
-7.05%
Top 10 Holdings %
Top 10 Hldgs %
50.13%
Holding
123
New
17
Increased
19
Reduced
10
Closed
18
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$28.5M |
| 2 |
AMED
Amedisys
AMED
|
$28.4M |
| 3 |
Revolution Medicines
RVMD
|
$24.7M |
| 4 |
Cabaletta Bio
CABA
|
$24.2M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$23M |
Top Sells
| 1 |
GeneDx Holdings
WGS
|
$333M |
| 2 |
Neurocrine Biosciences
NBIX
|
$50.5M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
$48.8M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$39.7M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$36.6M |
Sector Composition
| 1 | Healthcare | 68.03% |
| 2 | Financials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $843M | 18% | 19,991,024 | – | – |
|
2
Viatris
VTRS
$12.3B
| $177M | 3.77% | 17,703,484 +767,487 | +5% | +$7.66M |
|
|
AMED
3
DELISTED
Amedisys
AMED
| $164M | 3.5% | 1,794,000 +310,821 | +21% | +$28.4M |
|
4
AdaptHealth
AHCO
$1.28B
| $135M | 2.88% | 11,094,914 +500,000 | +5% | +$6.09M |
|
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $114M | 2.44% | 1,209,714 -535,000 | -31% | -$50.5M |
|
6
Catalyst Pharmaceutical
CPRX
$2.52B
| $110M | 2.35% | 8,192,000 -2,163,099 | -21% | -$29.1M |
|
|
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $94.4M | 2.02% | 6,707,026 +1,488,388 | +29% | +$21M |
|
8
Centene
CNC
$14.3B
| $91M | 1.94% | 1,349,000 +274,000 | +25% | +$18.5M |
|
9
Owens & Minor
OMI
$378M
| $90.3M | 1.93% | 4,745,000 +877,545 | +23% | +$16.7M |
|
10
Merus
MRUS
$4.98B
| $79.8M | 1.7% | 3,031,938 +651,500 | +27% | +$17.2M |
|
11
ARS Pharmaceuticals
SPRY
$1.15B
| $74.2M | 1.58% | 11,077,927 | – | – |
|
12
HilleVax
HLVX
$105M
| $57.2M | 1.22% | 3,329,231 +495,541 | +17% | +$8.52M |
|
13
Enhabit
EHAB
$399M
| $55.3M | 1.18% | 4,809,803 +1,411,057 | +42% | +$16.2M |
|
14
Brookdale Senior Living
BKD
$1.83B
| $53.5M | 1.14% | 12,679,651 -3,726,396 | -23% | -$15.7M |
|
15
IDEAYA Biosciences
IDYA
$2.15B
| $53.3M | 1.14% | 2,268,628 +525,000 | +30% | +$12.3M |
|
16
Larimar Therapeutics
LRMR
$310M
| $53M | 1.13% | 16,941,357 | – | – |
|
|
CMAX
17
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $49.3M | 1.05% | 15,861,090 | – | – |
|
|
18
Revolution Medicines
RVMD
$7.1B
| $46.9M | 1% | 1,751,496 +921,759 | +111% | +$24.7M |
|
19
Guardant Health
GH
$8.41B
| $44.9M | 0.96% | 1,253,999 +475,000 | +61% | +$17M |
|
|
SWTX
20
DELISTED
SpringWorks Therapeutics
SWTX
| $41.4M | 0.88% | 1,579,349 | – | – |
|
21
Cogent Biosciences
COGT
$1.69B
| $39.9M | 0.85% | 3,366,345 +400,000 | +13% | +$4.74M |
|
|
SILK
22
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $36.8M | 0.79% | 1,132,229 -593,411 | -34% | -$19.3M |
|
23
Kura Oncology
KURA
$686M
| $34.3M | 0.73% | 3,238,000 +855,000 | +36% | +$9.05M |
|
24
Edgewise Therapeutics
EWTX
$1.51B
| $30.5M | 0.65% | 3,933,137 | – | – |
|
|
25
Cabaletta Bio
CABA
$133M
| $30.2M | 0.65% | 2,340,118 +1,875,866 | +404% | +$24.2M |
|